Othman Al-Sawaf, MD

Articles

Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL

January 15th 2025

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

January 8th 2025

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

August 29th 2022

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL

June 12th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

Dr. Al-Sawaf on the Efficacy of Venetoclax/Obinutuzumab in Treatment-Naïve CLL

June 11th 2021

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Dr. Al-Sawaf on Efforts Examining Venetoclax/Obinutuzumab in CLL

February 24th 2021

Othman Al-Sawaf, MD, discusses research efforts that are evaluating the use of venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Next Steps of the CLL14 Trial in CLL

January 4th 2021

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Limitations of Continuous Therapy Administration in CLL

December 22nd 2020

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Dr. Al-Sawaf on New Safety Signals With Venetoclax/Obinutuzumab in the CLL14 Trial

August 4th 2020

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Dr. Al-Sawaf on Continual MRD Assessment ​After Venetoclax/Obinutuzumab in CLL

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

July 1st 2020

Othman Al-Sawaf, MD, discusses benefits of a fixed duration treatment versus continuous treatment in chronic lymphocytic leukemia.

Dr. Al-Sawaf on Updated PFS Data With Venetoclax Plus Obinutuzumab in CLL

June 11th 2020

Othman Al-Sawaf, MD, discusses updated data from the phase 3 CLL14 trial in chronic lymphocytic leukemia.

Dr. Al-Sawaf on Testing for CKT in CLL

November 8th 2019

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.